Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 7100769 | Gold and penicillamine therapy: is shared care with general practitioners effective and sa | 1982 Aug | One hundred patients with definite or classical rheumatoid arthritis were commenced on gold or penicillamine therapy. The patient's general practitioner was asked to participate in monitoring these patients. No reduction in efficacy or increase in serious adverse effects was present in this shared-care group. A 65% reduction in hospital clinic visits was achieved thus allowing more patients to benefit from this therapy. | |
| 4055878 | The management of infected total knee replacements. | 1985 Nov | A review of patients with an infected resurfacing prosthesis is presented. Eight patients with a loose infected prosthesis were treated by a one-stage exchange arthroplasty; six others with a well-fixed infected prosthesis were treated by drainage and antibiotics. All eight treated by exchange arthroplasty remained free of infection as did five of those treated by drainage. In four of these last five patients, the prosthesis was inserted without cement; the possible role of polymethylmethacrylate in the persistence of infection is discussed. | |
| 6787702 | Assessment of immune response during chrysotherapy. Comparison of gold sodium thiomalate v | 1981 | Auranofin (AF) differs significantly from gold sodium thiomalate (GST) in formulation, i.e., aurous gold is stabilized by dual sulfur and phosphorus ligands, has hydrophobic rather than hydrophilic characteristics, and lacks ionic charge. These attributes facilitate: oral absorption of AF, plasma membrane penetration, increase in intracellular lymphocyte gold concentration and perhaps thereby influence lymphocyte function. AF therapy was observed to affect primarily T rather than B lymphocyte function in 16 RA subjects receiving 6 mg of AF per day for an average of 45 weeks (range 20-74 weeks) compared with GST-treated RA subjects. Lymphocytes from AF-treated subjects manifested prompt and sharp declines in mitogen-induced lymphoproliferative response (LPR); suppressed response to skin testing with dinitrochlorobenzene (DNCB); and blebbing of lymphocyte membranes as shown by scanning electron microscopy. Suppression of LPR with AF was approximately 60% after the first week and 80% after 20 weeks of therapy, contrasting with 0% and 30% for the respective intervals in GST-treated subjects. DNCB skin testing of AF patients, indicated 11 of 14, failed to respond, whereas all GST patients responded. Local or systemic fungal, bacterial and/or opportunistic infections were not encountered. The effect of AF on B cell effector function, e.g., suppression of immunoglobulins and rheumatoid factor titer, was less marked when contrasted with GST therapy in RA subjects, as previously reported. | |
| 142735 | [Xeroradiography in the radiological diagnosis of the extremities and soft tissues (author | 1977 Jul | The authors carried out comparative examinations on 30 patients in order to determine whether xeroradiography had any advantages over film techniques in the examination of the soft tissues of the extremities. The xerograms show fatty degeneration of muscle fibres margins of individual muscles, calcification, oedema and so on, more clearly and are therefore of more value in diagnosis. The saving in time, using xerograms, is significant and conventional photo-copies can be obtained without logetronics. | |
| 6398313 | First observations on high-dosed and long-term thymopentin treatment in active rheumatoid | 1984 | In this pilot study carried out in two centres, six male and two female patients with severe active rheumatoid arthritis (RA) (average duration over 10 years) were treated with thymopentin 50 mg in the form of prolonged i.v. injection (over 10 min), 3 times weekly for 3 to 20 weeks. Two of these patients were subsequently treated with different s.c. doses of thymopentin in a crossover fashion for more than two years, including periods without any treatment or treatment with placebo. The overall clinical efficacy was judged by assessing pain patterns and joint status and the functional stage of the patients according to Steinbrocker; in addition, the sedimentation rate was measured before and after the therapy. Seven out of eight patients showed definite improvement in their clinical status as assessed by the Steinbrocker scale. Most of the symptoms, particularly pain, capsular swelling, tenderness and morning stiffness, were remarkably reduced within 3 weeks of thymopentin treatment. Sedimentation rate decreased in five out of eight patients. Prolonged i.v. injections seemed to have somewhat better effects than s.c. administration; in the latter group the highest dose (3 X 100 mg/week or higher) produced the best results. During placebo treatment and during the medication-free intervals both groups of patients got worse. No side-effects occurred during the study. | |
| 7005521 | [Clinical trial in couples of effectiveness and side-effects of gold and D-penicillamine i | 1980 Aug 15 | A prospective clinical trial in couples was done to compare effectiveness and toxicity of gold and D-penicillamine (D-Pen.) in treatment of rheumatoid arthritis (r.A.). Respecting defined criteria 70 patients were put to couples according to a random list and were treated with gold or D-Pen. alternatively. Physical and laboratory indices of inflammatory activity were checked every 3 months, X-rays every 12 months. Dropouts (side effects, missing compliance, uneffectiveness) were replaced by the nextcoming fitting patient. Thirty-two of 147 totally recruited patients stopped treatment because of side effects, three because of unsatisfying efficiency. Forty-two patients shuned the necessary controls. The clinical course was better in 16 couples with gold, only in sex couples with D-Pen. Thirteen pairs showed no difference in this respect (p = 0.05). Looking to the laboratory parameters separately D-Pen. tends to be superior (p < 0.05), radiografic deterioration seems to be more seldom with gold (< 0.05). Side effects occur with both drugs in comparable frequency (15/44 with D-Pen., 17/52 with gold), but the complications with D-Pen. are more serious. Altogether this trial shows gold superior to D-Pen. in the long-term treatment of r.A. | |
| 6324537 | Phagocytosis by normal polymorphonuclear leukocytes of immune complexes from serum of pati | 1984 Feb | Sera from patients with Felty's syndrome, rheumatoid arthritis (RA) and controls were investigated for the presence of immune complexes (IC) using phagocytosis by normal polymorphonuclear leukocytes and direct immunofluorescence technique. IC visible as large cytoplasmic inclusions were seen in 19 of 24 cases of Felty's syndrome, 3 of 16 cases of RA, and all 3 patients with extraarticular manifestations, and none of 21 control sera. IC containing IgG, IgA and complement C3 were found in nearly all positive cases. IgM IC were found in only 8 of the Felty's syndrome cases, IgE in 5 and beta-2-microglobulin in one case, respectively. A tendency to increasing number of large inclusion positive cells in vitro was found inversely correlated to the number of circulating leukocytes in the Felty patients at the time of serum sampling. In contrast, small cytoplasmic inclusions were found both in Felty's syndrome and RA patients and in some of the controls, and IgG and C3 were the most frequent constituents in these cases. As these inclusions were found in all groups it may have little significance. IgE IC as determined by a PEG precipitation technique were positive in the same 5 cases of Felty's syndrome with IgE containing inclusions, and in one case of RA with extraarticular manifestations. The complexed IgE amounted to about 3% of the total serum concentration of IgE. Phagocytosed IC may be involved in the pathogenesis of neutropenia and contribute to the inflammatory processes in Felty's syndrome. | |
| 6707057 | Telescoping osteotomy for pressure metatarsalgia. | 1984 Mar | A review is presented of 508 feet in 310 patients after telescoping osteotomy of the lesser metatarsals for metatarsalgia. The patients were predominantly female (80%), with a mean age of 55 years; the range of follow-up was 1 to 12 years. In 22% of the patients the metatarsalgia was associated with rheumatoid arthritis. Improvements in assessment and modifications in technique are reported and the management of complications is discussed. The results show that telescoping osteotomy for established cases of pressure metatarsalgia is a simple and reliable operation. Permanent relief of symptoms can be expected in over 80% of patients. | |
| 7037995 | [Studies on degradation of cartilage proteoglycan by rheumatoid synovial tissue. Part I: O | 1981 Nov | The degradation of MgCl2-extracted proteoglycans (PG) from bovine nasal and articular cartilage was performed by using human rheumatoid synovial tissue extract, and the products were compared with that of being degraded by different commercially available proteases. 2. Degradation of PG by crude synovial extract occurred under the wide range of pH, and the degradation products showed the changes as follows; 1) a decrease of viscosity, 2) a decrease of hydrodynamic size, 3) an increase of electrophoretic mobility, 4) no change of the length of glycosaminoglycan side chains, 5) an increase of chondroitin sulfate relative to keratan sulfate in precipitate with 1% cetylpyridinium chloride (CPC), and 6) an increase of serine content in precipitate with 1% CPC. 3. The average hydrodynamic size of degradation products by crude synovial extract was larger than that of degradation products by pronase or papain. 4. The results indicate that the proteases play the main role on the PG-degrading activity of rheumatoid synovial tissue extract but the glycosidase play no significant role. | |
| 6432415 | A single-blind comparative study of auranofin and hydroxychloroquine in patients with rheu | 1984 Mar | Forty patients with rheumatoid arthritis were randomly allocated to treatment with auranofin 3 mg b.d. or hydroxychloroquine 200 mg b.d. Twenty patients received each drug. Efficacy was analysed by comparing patients with available data at weeks 12, 24, 36 and 48 with baseline within each treatment group, and between treatment groups at each of these same time points. There were statistically significant improvements in all measured parameters of clinical efficacy among hydroxychloroquine treated patients, and in all efficacy parameters except one (time to onset of fatigue) in the auranofin treatment group. There were no significant differences between the treatment groups for any parameter of clinical efficacy. Of the laboratory parameters measured, only auranofin treatment produced statistically significant decreases in the concentration of IgA, IgG and IgM, with significant differences between treatments being detected in the case of IgA and IgG. Eight auranofin-treated and three hydroxychloroquine-treated patients were withdrawn because of adverse reactions before completing 48 weeks treatment. The commonest reason for stopping auranofin treatment was diarrhoea (5 cases). Three hydroxychloroquine-treated and two auranofin-treated patients were withdrawn from the study because of inefficacy of the trial drug. Auranofin had a more 'potent' biochemical profile than hydroxychloroquine, although more patients tolerated one year of treatment with the latter drug. | |
| 6343155 | A multicentre comparison of flurbiprofen and naproxen in rheumatoid arthritis: a four-week | 1983 | One-hundred and eighteen patients with rheumatoid arthritis were treated for 4 weeks with flurbiprofen 300 mg/day (sixty patients) or naproxen 750 mg/day (fifty-eight patients) in a six-centre randomized trial. Flurbiprofen proved to be more effective than naproxen in reducing morning stiffness (p less than 0.01), Ritchie articular index (p less than 0.01) and number of swollen joints (p less than 0.05) and in relieving night pain (p less than 0.01). The incidence and severity of side-effects, mainly gastric, were both low and similar with flurbiprofen (17%) and naproxen (19%). | |
| 6749576 | A comparative study of the effectiveness and safety of two non-steroidal anti-inflammatory | 1982 | A single-blind crossover study of two non-steroidal anti-inflammatory drugs, nabumetone (1000 mg/day) and naproxen (500 mg/day) was performed in thirty patients suffering from definite or classical rheumatoid arthritis. Nabumetone significantly improved the various parameters assessed, while this was not observed with naproxen. The superiority of nabumetone over naproxen appeared for the anti-inflammatory activity (e.g. E.S.R., articular index, P.I.P. joint circumference, grip strength) as well as for the analgesic activity (patient's opinion). The clinical tolerance appeared equally good for both drugs. | |
| 86203 | Demonstration of rheumatoid factor idiotypic antigens on peripheral blood B and T lymphocy | 1979 Mar | Antisera were raised against three polyclonal IgM rheumatoid factors (RF). After adequate absorptions, the antisera were rendered idiotype-specific, as assayed by haemagglutination technique. By using the anti-idiotype antisera in indirect immunofluorescence on peripheral blood lymphocytes from the patients used as donors for the immunizing RF, it was demonstrated that 3-14% of the lymphocytes were stained, and thus had membrane-bound structures with idiotypic antigens similar to those of the circulating IgM RF of the same patients. While most of these idiotype-positive lymphocyte were B lymphocytes, it was demonstrated in one patient that about 7% of the T lymphocytes also had the same idiotypic antigens. | |
| 1192631 | Results of low friction arthroplasty in patients thirty years of age or younger. | 1975 Oct | The results of total hip replacement in 39 patients 30 years old or younger were evaluated including 67 Charnley low-friction arthroplasties and one McKee total hip arthroplasty. The average age was 25.9 years with an average follow-up of 39 months, the longest being 8 years, 3 months. The diagnoses included rheumatoid arthritis, ankylosing spondylitis, CDH, Still's disease, and a miscellaneous group. Over-all function did not improve as greatly as in the 9 to 10 year series, but this was due to a higher proportion of patients with severely disabling rheumatoid polyarthritis, hemiplegia, severe obesity, or cardiovascular disease. Wear did not seem to be any greater in this younger age group as compared to previous studies in older patients. | |
| 6354607 | Double-blind evaluation of low-dose proglumetacin versus naproxen in rheumatoid arthritis | 1983 | Forty out-patients with acute 'flare' of chronic rheumatoid arthritis were treated orally with either 150 mg proglumetacin or 250 mg naproxen twice daily over 3 weeks, according to a randomized, double-blind design. Before and after 1 and 3 weeks of treatment, the number of painful and of swollen joints, the intensity of pain and function tests (morning stiffness, time to walk over 15 metres and hand grip strength) were measured and recorded. Haematology was investigated before and after treatment. Two patients in the proglumetacin group did not report to control and were considered drop-outs; 2 more (1 in each group) interrupted treatment before completion because of the onset or aggravation of accessory symptoms. Efficacy, assessed in 17 patients on proglumetacin and in 19 on naproxen, was good with both drugs, even though only those patients given proglumetacin experienced a significant (p less than 0.01) decrease in the number of painful joints. None of the haematological tests showed clinically significant variations after either treatment. Tolerance could be assessed in 18 and 20 patients given proglumetacin or naproxen, respectively. Accessory symptoms appeared or were aggravated in 5 and 3 patients, respectively. | |
| 7004474 | Indomethacin in rheumatoid arthritis: comparison of oral and rectal dosing. | 1980 Oct | 1 Indomethacin 100 mg nightly for 1 week has been administered to 13 patients with rheumatoid arthritis by both oral and rectal routes in a double-blind, randomized, cross-over study. 2 Clinical assessments were performed at 09.00 and 14.00 h on the last 3 days of each active treatment period and compared to the results on the last 2 days of the placebo control period. 3 Indomethacin produced significant improvements in the clinical assessments at both 09.00 and 14.00 h compared to placebo but not differences were seen between the two routes of administration. 4 No significant difference was seen in the side effects experienced in the two periods. 5 The mean (+/- s.e. mean) plasma indomethacin concentration at 09.00 h in the oral period was 200.3 +/- 27.4 ng/ml, not significantly different from that in the suppository period (220.0 +/- 28.9 ng/ml). 6 Indomethacin 100 mg nightly by mouth is as effective as a 100 mg suppository and easier to administer. | |
| 141355 | Intramuscular gold for rheumatoid arthritis. | 1977 Jun | Improvement from gold therapy is not immediate but comes about very slowly. The patient and physician should be forewarned that as many as 8 to 14 weeks may pass before any benefit is noted, and that months of treatment may be required before improvement is sufficient to decrease disability. With effective therapy, signs of inflammation gradually decrease, pain abates, and function improves. Not all patients benefit, and whether beneficial results occur can be determined only by clinical trial. There is no advance method of determining whether treatment will be effective. Gold therapy suppresses rheumatoid inflammation and checks the progress of the disease. It should not be used alone, but shoud be part of a well-planned program of treatment carefully adjusted to the needs of the individual. This therapy will include steroidal and nonsteroidal anti-inflammatory agents (including aspirin), which should not be reduced or abandoned until definite improvement from gold can be determined. With the possible exception of palindromic and juvenile forms, RA is the only rheumatic disease benefited by intramuscular gold therapy. The treatment should never be used for other forms of rheumatism. | |
| 6742916 | Listeria monocytogenes septic arthritis following intra-articular yttrium-90 therapy. | 1984 Jun | Listeria monocytogenes is a rare cause of septic arthritis, which usually occurs in a host compromised by systemic illness. Intra-articular irradiation with yttrium-90 is generally free of complication. We report a case of intra-articular sepsis of the knee joint by Listeria monocytogenes acquired under unusual circumstances. | |
| 6731056 | Use of acrylic prosthesis in cervical spine pathology (report of 45 cases). | 1984 | The authors report on their experience with the use of a reinforced acrylic prosthesis in cervical spine pathology. The study of their own 45 cases enables the advantages and disadvantages of the technique to be demonstrated. A discussion of possible improvements in the technique and its indication completes the report. | |
| 6723128 | Selected adverse reactions of D-penicillamine. | 1984 | Selected adverse reactions of penicillamine encountered in our clinic since 1975 are described. They include: proteinuria (26 cases), lupus erythematosus (six cases), myasthenia gravis (two cases), pemphigus (three cases), obliterative bronchiolitis (two cases) and obstructive jaundice (one case). |